S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Structure Therapeutics (GPCR) Stock Price, News & Analysis

$61.87
+2.01 (+3.36%)
(As of 12/8/2023 ET)
Compare
Today's Range
$58.94
$62.85
50-Day Range
$47.95
$74.30
52-Week Range
$20.80
$75.02
Volume
348,461 shs
Average Volume
751,290 shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.14

Structure Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
31.2% Upside
$81.14 Price Target
Short Interest
Healthy
8.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.86) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

543rd out of 933 stocks

Pharmaceutical Preparations Industry

246th out of 431 stocks


GPCR stock logo

About Structure Therapeutics Stock (NASDAQ:GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Stock Price History

GPCR Stock News Headlines

Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up to $55.69
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Structure Therapeutics Inc ADR
11 Best Young Stocks to Buy and Hold For 20 Years
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
What 6 Analyst Ratings Have To Say About Structure Therapeutics
Structure Therapeutics Inc ADR GPCR Stock Quote
4 Analysts Have This to Say About Structure Therapeutics
Why Shares of Structure Therapeutics Are Up Monday
See More Headlines
Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GPCR
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$81.14
High Stock Price Target
$97.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+31.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-51,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.87 billion
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Raymond C. Stevens Ph.D. (Age 59)
    CEO & Director
    Comp: $747.33k
  • Dr. Yingli Ma Ph.D. (Age 49)
    Chief Technology Officer
    Comp: $497.58k
  • Dr. Mark A. Bach M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $628.37k
  • Mr. Jun S. Yoon (Age 45)
    Co- Founder, CFO & Secretary
  • Dr. Xichen Lin Ph.D. (Age 49)
    Chief Scientific Officer
  • Mr. Tony Peng
    Senior Vice President of Legal
  • Mr. Bob Gatmaitan
    Senior Vice President of People
  • Dr. Hui Lei Ph.D.
    Senior Vice President of Chemistry
  • Dr. Fang Zhang Ph.D.
    Executive VP & Head of Biology
  • Ms. Lani Ibarra
    Senior Vice President of Clinical Development Operations














GPCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings
or view top-rated stocks.

What is Structure Therapeutics' stock price target for 2024?

7 equities research analysts have issued 12 month target prices for Structure Therapeutics' shares. Their GPCR share price targets range from $33.00 to $97.00. On average, they expect the company's stock price to reach $81.14 in the next year. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for GPCR
or view top-rated stocks among Wall Street analysts.

How have GPCR shares performed in 2023?

Structure Therapeutics' stock was trading at $26.00 on January 1st, 2023. Since then, GPCR shares have increased by 138.0% and is now trading at $61.87.
View the best growth stocks for 2023 here
.

When is Structure Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our GPCR earnings forecast
.

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. (NASDAQ:GPCR) announced its earnings results on Tuesday, November, 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01.

What ETFs hold Structure Therapeutics' stock?

ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Fidelity Disruptive Medicine ETF (FMED).

When did Structure Therapeutics IPO?

(GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Adage Capital Partners GP L.L.C. (4.70%), FMR LLC (4.16%), Federated Hermes Inc. (2.90%), Wellington Management Group LLP (1.87%), Monashee Investment Management LLC (1.66%) and Avidity Partners Management LP (1.31%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GPCR) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -